Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas
- PMID: 11597812
- DOI: 10.1016/s0360-3016(01)01705-9
Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas
Abstract
Purpose: To document the incidence of tumor progression in pediatric patients with low-grade gliomas (LGGs), with particular emphasis on those patients who did not receive postoperative chemotherapy or radiotherapy (RT).
Methods and materials: A database of 128 patients with histologically confirmed LGGs (World Health Organization Grade I-II), age <or=18 years, who had been referred to the London Regional Cancer Center and Dalhousie University between 1979 and 1995, was compiled.
Results: The median follow-up for the 128 patients was 7.3 years. Of the 128 patients, 63 were male and 65 female. The median age was 7.0 years (range 0-18). Twenty-five patients underwent gross complete resection, 63 subtotal resection, and 40 patients biopsy. Ninety-one percent (n = 117) of the tumors were astrocytomas, of which 22 were pilocytic, 3 were oligodendrogliomas, 7 were mixed gliomas, and 1 was a ganglioglioma. Of the 103 subtotally resected patients, 48 received postoperative RT (median dose 59 Gy in 25 fractions) and 10 patients were irradiated at the time of tumor progression. The 5-year overall survival was 86%, cause-specific survival 88%, and 5-year progression-free survival 79%. The results of the univariate analysis of the overall survival by the Wilcoxon model were statistically significant for Karnofsky performance status (p = 0.03), RT timing (i.e., postoperative vs. deferred; p = 0.05), and tumor location (p = 0.02). The analysis of progression-free survival confirmed the statistical significance of the extent of surgical resection (i.e., complete vs. subtotal resection; p = 0.02). None of the patients who underwent gross complete resections received postoperative RT and none developed tumor recurrence. Of the 103 patients who had subtotal resections, 33 had progression, with a median postprogression survival of 39 months. The rate of tumor progression among the subtotally resected LGG patients who did not receive immediate postoperative RT was 42%. The timing of RT and tumor location lost statistical significance for overall survival when the completely resected patients were excluded from the analysis.
Conclusions: The extent of surgical resection was prognostically significant for progression-free survival but lost significance as a prognostic factor once the complete resection patients were excluded from the analysis. At a median survival of 7.3 years, 42% of the subtotally resected LGG patients who did not receive immediate postoperative RT had tumor progression. No statistically significant difference in survival was seen between the postoperative and deferred RT groups, even though the postoperative RT group was a group with poorer prognostic features (bulky residual tumor postoperatively, Karnofsky performance status <70, and nonhemispheric, noncerebellar tumors), indicating that RT may be beneficial for this particular subset of patients.
Similar articles
-
Role of early radiotherapy in the treatment of supratentorial WHO Grade II astrocytomas: long-term results of 97 patients.J Neurooncol. 2003 Jul;63(3):305-12. doi: 10.1023/a:1024376719067. J Neurooncol. 2003. PMID: 12892238
-
Adult low-grade glioma: 19-year experience at a single institution.Am J Clin Oncol. 2013 Dec;36(6):612-9. doi: 10.1097/COC.0b013e31825d580a. Am J Clin Oncol. 2013. PMID: 22892428 Free PMC article.
-
Supratentorial astrocytomas and oligodendrogliomas treated in the MRI era.Jpn J Clin Oncol. 2001 Jun;31(6):240-5. doi: 10.1093/jjco/hye052. Jpn J Clin Oncol. 2001. PMID: 11463800
-
Prospective clinical trials of intracranial low-grade glioma in adults and children.Neuro Oncol. 2003 Jul;5(3):153-60. doi: 10.1215/S1152851702000601. Neuro Oncol. 2003. PMID: 12816721 Free PMC article. Review.
-
Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):390-7. doi: 10.1016/j.ijrobp.2009.08.029. Epub 2010 Jan 25. Int J Radiat Oncol Biol Phys. 2010. PMID: 20097489 Review.
Cited by
-
Platinum compounds and sodium metabolism in children with diencephalic glioma.J Neurooncol. 2013 Oct;115(1):113-7. doi: 10.1007/s11060-013-1203-6. Epub 2013 Jul 10. J Neurooncol. 2013. PMID: 23839227
-
Treatments for astrocytic tumors in children: current and emerging strategies.Paediatr Drugs. 2006;8(3):167-78. doi: 10.2165/00148581-200608030-00003. Paediatr Drugs. 2006. PMID: 16774296 Review.
-
Advances in the management of low-grade gliomas.Curr Oncol Rep. 2014;16(8):398. doi: 10.1007/s11912-014-0398-9. Curr Oncol Rep. 2014. PMID: 24925153 Review.
-
Medical Treatment of Pediatric Low-Grade Glioma.Brain Tumor Res Treat. 2022 Oct;10(4):221-225. doi: 10.14791/btrt.2022.0039. Brain Tumor Res Treat. 2022. PMID: 36347636 Free PMC article. Review.
-
The efficacy of radiation therapy in the management of grade I astrocytomas.J Neurooncol. 2006 Jan;76(1):55-8. doi: 10.1007/s11060-005-2913-1. Epub 2005 Aug 11. J Neurooncol. 2006. PMID: 16132503
MeSH terms
LinkOut - more resources
Full Text Sources
Medical